SLNO Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 59.82%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1694.28%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -1.471, which suggesting that the stock is 247.077% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$76.6M is lower than CEL-SCI's net income of -$6.9M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,202.57x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Kronos Bio has a net margin of -- compared to Soleno Therapeutics's net margin of -595.27%. Soleno Therapeutics's return on equity of -- beat Kronos Bio's return on equity of -60.36%.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 59.82%. On the other hand Kronos Bio has an analysts' consensus of -- which suggests that it could grow by 125%. Given that Kronos Bio has higher upside potential than Soleno Therapeutics, analysts believe Kronos Bio is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -1.471, which suggesting that the stock is 247.077% less volatile than S&P 500. In comparison Kronos Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kronos Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Kronos Bio pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Kronos Bio quarterly revenues of $2.4M. Soleno Therapeutics's net income of -$76.6M is lower than Kronos Bio's net income of -$14.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Kronos Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,202.57x versus 6.04x for Kronos Bio. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -54.2%. Soleno Therapeutics's return on equity of -- beat PTC Therapeutics's return on equity of --.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 59.82%. On the other hand PTC Therapeutics has an analysts' consensus of $57.14 which suggests that it could grow by 26.16%. Given that Soleno Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Soleno Therapeutics is more attractive than PTC Therapeutics.

Soleno Therapeutics has a beta of -1.471, which suggesting that the stock is 247.077% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Soleno Therapeutics's net income of -$76.6M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,202.57x versus 3.95x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of 37.71%. Soleno Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 59.82%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 21.25%. Given that Soleno Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Vertex Pharmaceuticals.

Soleno Therapeutics has a beta of -1.471, which suggesting that the stock is 247.077% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Soleno Therapeutics's net income of -$76.6M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,202.57x versus 9.97x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.